The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| BIOMARIN PHARMACEUTICAL INC | COM | 09061G101 | 22,718 | 182,300 | SH | SOLE | 182,300 | 0 | 0 | ||
| HERON THERAPEUTICS INC | COM | 427746102 | 66,876 | 4,596,318 | SH | SOLE | 4,596,318 | 0 | 0 | ||
| HERON THERAPEUTICS INC | COM | 427746102 | 4,704 | 323,307 | SH | OTR | 1 | 0 | 323,307 | 0 | |
| LA JOLLA PHARMACEUTICAL CO | COM | 503459604 | 38,458 | 2,101,547 | SH | SOLE | 2,101,547 | 0 | 0 | ||
| LA JOLLA PHARMACEUTICAL CO | COM | 503459604 | 784 | 42,840 | SH | OTR | 1 | 0 | 42,840 | 0 | |
| MERRIMACK PHARMACEUTICALS INC | NOTE 4.5% 7/15/20 | 590328AA8 | 11,154 | 5,500,000 | PRN | SOLE | 5,500,000 | 0 | 0 | ||
| MIRATI THERAPEUTICS INC | COM | 60468T105 | 11,392 | 388,543 | SH | SOLE | 388,543 | 0 | 0 | ||
| ONCOGENEX PHARMACEUTICALS INC | COM | 68230A106 | 1,351 | 628,400 | SH | SOLE | 628,400 | 0 | 0 | ||
| OPKO HEALTH INC | DEBT 3.0% 2/1/33 | 68375NAB9 | 29,439 | 14,000,000 | PRN | SOLE | 14,000,000 | 0 | 0 | ||
| RXI PHARMACEUTICALS CORP | COM | 74979C303 | 1,132 | 1,572,699 | SH | SOLE | 1,572,699 | 0 | 0 | ||